Exagen Inc. Reports Second Quarter 2026 Financial Results
Exagen Inc. (Nasdaq: XGN) reported Q2 2026 results for the quarter ended June 30. Total revenue rose to $19.9 million, up 16% year over year, with AVISE CTD test volume up 11% and trailing twelve-month ASP at $446. Adjusted EBITDA loss narrowed to $0.1 million. Full-year 2026 revenue guidance increased to $72 to $75 million.
How this was made
The 30-second read
Why it matters
The key tradable elements are the raised FY2026 revenue guidance ($72M-$75M vs $70M-$73M), record Q2 revenue and test volume growth, higher trailing-twelve-month ASP, and a narrowed adjusted EBITDA loss to $0.1M.
Market read
A guidance raise paired with improved adjusted EBITDA and record revenue/test-volume metrics can shift expectations for operating leverage in a small-cap diagnostics name.
What to watch
The press release emphasizes non-GAAP adjusted EBITDA; traders may scrutinize GAAP operating loss trajectory, cash burn dynamics beyond ending cash, and whether ASP/test-volume gains are durable.
Background
Exagen is an autoimmune diagnostics company focused on AVISE CTD testing; this release covers Q2 2026 results and updated full-year guidance.
Ticker impact
Exagen (XGN) reported Q2 results with record revenue of $19.9M, improved adjusted EBITDA loss to $0.1M, and raised FY2026 revenue guidance to $72M-$75M.
Likely positive bias for the stock into the next trading sessions as investors digest the raised revenue range and EBITDA narrowing.
The article discloses multiple fresh, decision-relevant datapoints: Q2 revenue growth, ASP and test volume trends, adjusted EBITDA improvement, ending cash, and an explicit FY guidance raise. However, it is still a loss-making quarter, limiting conviction on sustained profitability timing.
Market effects
Supports sentiment for autoimmune diagnostics providers by highlighting real-world evidence and improving unit economics (ASP and adjusted EBITDA).
Limited, company-specific impact likely confined to small-cap biotech/diagnostics sentiment.
Low; no cross-border regulatory or commercial deal details disclosed.
Counterpoint
Despite guidance lift, Exagen remains loss-making on GAAP net loss and adjusted EBITDA is still negative, so the market may demand proof of sustained cash generation before re-rating.
Key entities
- companyExagen Inc.
Nasdaq-listed autoimmune diagnostics provider reporting Q2 2026 results and raising FY2026 revenue guidance.
- productAVISE CTD
Flagship autoimmune testing offering referenced for test volume and ASP trends.
- executiveJohn Aballi
CEO who commented on progress toward sustainable profitability and cash generation.
